Clarify Medical said today that it won reimbursement coverage through the U.S. Centers for Medicare & Medicaid Services for treatments with its Clarify Home light therapy system for treating psoriasis, effective immediately.
The new decision from CMS falls under its National Coverage Determination for the treatment of psoriasis, which includes narrowband ultraviolet B phototherapy, San Diego-based Clarify Medical said.
The company’s Clarify system uses narrowband ultraviolet B rays to penetrate the skin and slow the growth of affected skin cells. Studies have found that narrowband UVB rays help to clear psoriasis faster compared to broadband UVB, according to Clarify Medical.
Clarify’s system is handheld and meant for use at home, and can also be synced with a user’s smartphone. Once the device is connected via iPhone or Android, the user can control and customize the dosage, frequency and duration of their treatment, Clarify said.
“This is a significant milestone for Clarify and the patients we serve. Not only does this decision enable millions of Medicare beneficiaries to treat their psoriasis using the Clarify System, but it also enables the company to begin establishing coverage with private medical insurance plans, which we are already pursuing in earnest. Our mission now is to make our System accessible and affordable for as many patients as possible,” prez & CEO George Mahaffey said in a press release.
Last July, Clarify Medical said that it raised $1 million from seven investors as part of a $1.5 million offering.
